Orchestra BioMed Inc. (OBIO)
4.12
-0.57 (-12.15%)
At close: Mar 03, 2025, 3:59 PM
4.10
-0.49%
After-hours: Mar 03, 2025, 04:00 PM EST
No 1D chart data available
| Bid | 4.1 |
| Market Cap | 156.62M |
| Revenue (ttm) | 2.67M |
| Net Income (ttm) | -58.29M |
| EPS (ttm) | -1.6 |
| PE Ratio (ttm) | -2.58 |
| Forward PE | -2.79 |
| Analyst | Buy |
| Ask | 4.1 |
| Volume | 81,743 |
| Avg. Volume (20D) | 98,215 |
| Open | 4.73 |
| Previous Close | 4.69 |
| Day's Range | 4.11 - 4.75 |
| 52-Week Range | 3.96 - 8.87 |
| Beta | 0.56 |
About OBIO
Orchestra BioMed Holdings, Inc. operates as a biomedical innovation company. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension; and Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic artery disease. Its products also comprise FreeHold retractors that are minimally invasive surgical device solutions. The company has a strategic collabora...
Industry Biotechnology
Sector Healthcare
IPO Date Aug 4, 2020
Employees 56
Stock Exchange NASDAQ
Ticker Symbol OBIO
Website https://orchestrabiomed.com
Analyst Forecast
According to 4 analyst ratings, the average rating for OBIO stock is "Buy." The 12-month stock price forecast is $15.5, which is an increase of 276.20% from the latest price.
Buy 100.00%
Hold 0.00%
Sell 0.00%
Next Earnings Release
Orchestra BioMed Inc. is scheduled to release its earnings on Mar 26, 2025,
during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
2 months ago
+34.5%
Orchestra BioMed shares are trading higher Barclay...
Unlock content with
Pro Subscription
